瑞普生物(300119) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 reached ¥647,768,241.19, an increase of 9.22% year-over-year, while year-to-date revenue was ¥1,746,806,365.21, up 10.06% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥85,597,145.56, a decrease of 10.30% year-over-year, with year-to-date net profit at ¥244,736,518.03, down 10.58%[2] - Basic earnings per share for Q3 2024 was ¥0.1857, reflecting a decline of 9.72% compared to the same period last year[2] - The net profit for Q3 2024 was CNY 264.18 million, a decrease of 10.5% compared to CNY 294.90 million in Q3 2023[17] - The total comprehensive income for the period was CNY 264.18 million, compared to CNY 294.90 million in the same quarter last year, indicating a decline of 10.5%[18] - Basic and diluted earnings per share were both CNY 0.5313, down from CNY 0.5900 in Q3 2023[18] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥7,435,784,609.90, representing a 12.73% increase from the end of the previous year[2] - The total liabilities rose to CNY 2,477,936,933.07, compared to CNY 1,791,055,573.41, marking a significant increase of 38.34%[15] - The non-current assets totaled CNY 4,087,412,944.91, which is an increase of 22.66% from CNY 3,332,613,794.00[14] - The company's equity attributable to shareholders increased to CNY 4,549,883,109.64 from CNY 4,496,304,113.26, a rise of 1.19%[15] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥356,123,557.72 for the year-to-date, which is an increase of 80.80% compared to the same period last year[6] - The cash flow from operating activities generated a net amount of CNY 356.12 million, compared to CNY 196.97 million in Q3 2023, reflecting a significant increase of 80.7%[19] - The total cash inflow from investment activities was CNY 2.60 billion, while cash outflow was CNY 2.84 billion, resulting in a net cash outflow of CNY 231.23 million[19] - Cash used for debt repayment in Q3 2024 was approximately ¥289.33 million, compared to ¥638.99 million in Q3 2023, indicating a decrease of about 54.7%[20] - Cash flow from financing activities showed a net outflow of ¥110.40 million in Q3 2024, an improvement from a net outflow of ¥350.70 million in Q3 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,417[7] - The largest shareholder, Li Shoujun, holds 35.95% of shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[7] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Liang Wu, owning 5.09% or 23,716,898 shares[7] - The company completed the repurchase and cancellation of 428,280 restricted stock units from the 2022 incentive plan, reducing the total share capital to 465,847,906 shares[11] - The company has not reported any changes in the number of preferred shareholders or their holdings[9] Operational Performance - The total operating revenue for the third quarter of 2024 reached CNY 1,746,806,365.21, an increase of 10.04% compared to CNY 1,587,164,776.49 in the same period last year[16] - The total operating costs amounted to CNY 1,466,821,630.31, reflecting a year-over-year increase of 11.59% from CNY 1,314,397,482.78[16] - The company's operating profit decreased to CNY 304.08 million, down 6.9% from CNY 326.72 million in the previous year[17] - Research and development expenses rose to CNY 135.16 million, an increase of 8.4% from CNY 124.18 million in Q3 2023[17] - The company reported an increase in sales expenses to CNY 287.79 million, up from CNY 266.62 million in the previous year, marking a rise of 7.9%[17] - The financial expenses increased to CNY 18.12 million, compared to CNY 14.34 million in Q3 2023, reflecting a rise of 26.5%[17] Changes and Future Outlook - The company has a strategy to expand its market presence, as indicated by the ongoing development of new products and technologies[8] - The report indicates that there are no significant changes in the participation of major shareholders in margin trading activities[8] - The company is committed to maintaining transparency regarding shareholder equity and incentive plans[11] - The company has not yet audited the Q3 2024 report, which may affect the reliability of the financial data presented[21] - The company implemented new accounting standards starting in 2024, which may impact the financial reporting and analysis moving forward[20]